← Eichor
Study identifier: NCT05630963 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression

Condition: Major Depressive Disorder  ·  Sponsor: Mclean Hospital

PhaseN/A
Planned participants228
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.

This description comes directly from the study's public registry record.

Talk to the study team

Tracy Lam, BS  ·  617-855-4437  ·  mclrew41study@mgb.org

David Crowley, ALM  ·  617-855-4432  ·  djcrowley@mclean.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

McLean HospitalBelmont, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05630963